Coadministration of encorafenib with sensitive CYP3A4 substrates could bring about elevated toxicity or lowered efficacy of these agents.withdrawal reactions, which includes seizures, which may be lifetime-threatening; use gradual taper when discontinuing therapy to cut back withdrawal reactions riskWatch Intently (1)oxcarbazepine will lessen the l